PUREVAX Feline Rabies

Rabies Vaccine

Live Canarypox Vector

rRabies

SWD

DESCRIPTION: PUREVAX^® Feline Rabies contains a nonadjuvanted lyophilized suspension of a recombinant vectored rabies vaccine plus a sterile water diluent. A canarypox vector has been modified, using recombinant technology, to produce expression of desired antigens capable of stimulating a protective immune response to rabies. Safety and immunogenicity of this product have been demonstrated by vaccination and challenge tests in susceptible cats.

INDICATIONS: PUREVAX^® Feline Rabies is recommended for the vaccination of healthy cats 12 weeks of age and older for prevention of disease due to rabies virus.

DOSAGE: Reconstitute the lyophilized vaccine with accompanying liquid diluent and aseptically inject 1 mL (1 dose) subcutaneously into healthy cats. Revaccinate annually with a single 1 mL dose.

PRECAUTIONS: Store at 2-7°C (35-45°F). Use immediately after reconstitution. Do not use chemicals to sterilize syringes and needles. Burn this container and all unused contents. Contains gentamicin as a preservative. It is generally recommended to avoid vaccination of pregnant cats. In rare instances, administration of vaccines may cause lethargy, fever, and inflammatory or hypersensitivity types of reactions. Treatment may include antihistamines, anti-inflammatories, and/or epinephrine.

SOLD TO VETERINARIANS ONLY.

For Veterinary Use Only.

PUREVAX is a registered trademark of MERIAL.

Manufactured By MERIAL INC., Athens, GA 30601 USA

U.S. Vet. Lic. No. 298

1-888-Merial-1 (1-888-637-4251)

Distributed In Canada By MERIAL CANADA, INC., Baie d’Urfé, (Québec), H9X 3V1, Canada

CPN: 11110584